eszopiclone (Lunesta)

04/01/2011 - "In this post hoc analysis of patients with insomnia and comorbid anxious depression derived from 2 trials, 8 weeks of eszopiclone therapy coadministered with an SSRI resulted in significantly greater improvements in insomnia, significantly greater reductions in HDRS-17 total score, and significantly greater HDRS-17 response rates compared with placebo coadministration. "
02/01/2010 - "In this Phase IV trial of older adults with insomnia, eszopiclone significantly improved patient-reported sleep and daytime function relative to placebo. "
01/01/2007 - "A decision analytical model was developed based on the reanalysis of a 6-month placebo-controlled trial, which demonstrated that eszopiclone 3mg significantly improved sleep and daytime function measures versus placebo in adults with primary insomnia. "
02/01/2006 - "In clinical trials, eszopiclone 3 mg significantly improved objective and subjective sleep measures in transient and chronic insomnia in adults. "
12/01/2012 - "In Japanese patients with primary insomnia, eszopiclone 2mg and 3mg significantly improved PSG-determined and patient-reported sleep latency and sleep maintenance relative to placebo."

03/01/2010 - "Eszopiclone is effective for the treatment of insomnia in patients with insomnia and comorbid major depressive disorder (MDD). "
03/01/2010 - "Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder."
01/01/2005 - "Preliminary results from a completed phase IIIB/IV trial report that eszopiclone in combination with fluoxetine significantly improved sleep parameters among patients with insomnia and co-existing major depressive disorder. "
06/01/2006 - "Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder."

01/01/2011 - "Thus, in this study, eszopiclone did not improve sleep sufficiently to improve fatigue in MS patients. "
12/01/2011 - "There were no significant differences between eszopiclone and placebo in terms of self-reports of fatigue or opioid usage. "
01/01/2011 - "Thirty ambulatory adults under age 65 years with RRMS, fatigue, and sleep disturbances were randomized to receive either eszopiclone or placebo. "
12/01/2011 - "This study examined whether treatment with the sedative hypnotic eszopiclone could improve self-reports of sleep, fatigue, and pain as well as decrease opioid self-administered via PCA. "
01/01/2011 - "Effect of eszopiclone on sleep disturbances and daytime fatigue in multiple sclerosis patients."

12/01/2014 - "On further analysis there was a significant improvement in the working memory test, letter-number span component of MATRICS (mean=9.8±9.2, z=-2.00, p=0.045) only for subjects with schizophrenia on eszopiclone. "
12/01/2014 - "Sleep remained improved during single-blind placebo phase after eszopiclone was stopped, but the working memory improvement in patients with schizophrenia was not durable. "
09/01/2013 - "The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized placebo-controlled trial."
09/01/2013 - "These findings provide partial support for the hypothesis that the spindle deficit in schizophrenia impairs sleep-dependent memory consolidation and may be ameliorated by eszopiclone. "
09/01/2013 - "We investigated whether eszopiclone could increase spindles and thereby improve memory consolidation in schizophrenia. "

12/01/2011 - "Mean pain scores were lower in the eszopiclone group at all time points (morning p = 0.01, afternoon p = 0.04, evening p = 0.04). "
01/01/2009 - "In this pilot study of patients with insomnia comorbid with RA, eszopiclone 3 mg improved all assessed sleep and daytime function measures over the treatment period, as well as some measures of RA-associated pain, disability, and quality of life. "
12/01/2011 - "This study examined whether treatment with the sedative hypnotic eszopiclone could improve self-reports of sleep, fatigue, and pain as well as decrease opioid self-administered via PCA. "
01/01/2009 - "Eszopiclone was significantly better than placebo on some RA-associated pain measures: (1) overall (P = .05), pain (P = .006), and pain and other symptoms (P = .02) scores of the Arthritis Self-Efficacy Scale, (2) tender joint counts (P = .03) and pain severity scores (P = .023), (3) the activities domain of the Health Assessment Questionnaire-Disability Index (P = .04), and (4) the role physical (P = .03) and bodily pain (P = .01) scales of the 36-item Medical Outcomes Study Short-Form General Health Survey. "
12/01/2011 - "Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies."